Join
Live feed
·
INSIDERFilingvia Quantisnow
Heron Therapeutics Inc. logo

Chief Operating Officer Hensley Mark Earl converted options into 125,000 shares, increasing direct ownership by 1,062% to 136,770 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
HRTX· Heron Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HRTX (Heron Therapeutics Inc.) and more on Quantisnow.